Ozone Therapy / Major Autohemotherapy (MAH) — Blood & Plasma Interventions
Withdrawal of blood, ozonation ex vivo, and reinfusion — used in integrative medicine for anti-inflammatory, antimicrobial, and metabolic effects. Controversial outside Europe.
Overview
Major Autohemotherapy (MAH) involves withdrawing 100-200 mL of blood, mixing it with ozone/oxygen gas (O3/O2 mixture) in a sealed bottle, and reinfusing the ozonated blood. Ozone (O3) at controlled concentrations is a potent oxidizing agent. When blood is ozonated, it triggers an acute controlled oxidative stress response, inducing the Nrf2 pathway and upregulating endogenous antioxidant defenses (superoxide dismutase, catalase, glutathione peroxidase) — a mechanism called 'oxidative preconditioning.' Ozone therapy is widely used in Europe (particularly Italy, Germany, Spain) where it is an accepted complementary medical treatment, with the International Scientific Committee of Ozone Therapy (ISCO3) and Madrid Declaration providing guidelines. In the USA, FDA has not approved any ozone-generating device for human treatment, and the American Cancer Society and medical mainstream consider it unproven. Evidence exists for specific conditions: a systematic review found benefit in knee osteoarthritis (intra-articular injection), diabetic foot ulcers, and lumbar disc herniation. Antimicrobial properties of ozone are well-established — used in dental, water treatment, and food safety applications.
Indications
- Chronic infections (Lyme disease, EBV — integrative use, controversial)
- Knee osteoarthritis (intra-articular injection — moderate evidence)
- Diabetic foot ulcer wound healing
- Chronic fatigue and immune dysregulation (integrative use)
- Anti-inflammatory and antioxidant preconditioning
Mechanism of Action
Controlled ozone exposure creates transient oxidative stress that activates the Nrf2/Keap1 pathway — upregulating antioxidant response element genes including SOD, catalase, glutathione peroxidase, and heme oxygenase-1
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| MAH (Major Autohemotherapy) | 100-200 mL blood withdrawn, ozonated with 70-100 μg/mL O3 concentration, reinfused | 1-3 sessions per week for initial series; monthly maintenance | Available at integrative medicine clinics; cost $100-300/session; 10-session initial series common |
| Rectal Ozone Insufflation (ROHI) | 100-200 mL ozone/oxygen gas rectally administered | 3-5x per week for initial series | Lower risk alternative to MAH; similar systemic effects via colonic absorption; self-administrable after clinic training |
Evidence Grade
GRADE C
Safety & Contraindications
- Ozone must NEVER be inhaled — even brief inhalation causes severe pulmonary damage, oxidative injury to airways; must be administered only via blood (MAH), rectally, intra-articularly, topically, or via sealed device
- FDA has not cleared any ozone device for systemic use in USA; available only in integrative/alternative medicine clinics
- Blood handling and reinfusion carries risk of air embolism if procedure not performed correctly
- Theoretical: in individuals with G6PD deficiency, ozone oxidative stress can trigger hemolytic anemia
- Quality and purity of ozone/oxygen mixture depends entirely on equipment and practitioner skill